Breast Cancer
-
Virtual Connection in a Time of Social DistanceResponding to the coronavirus, patient advocates and nonprofits expand existing outreach initiatives and launch new ones.
by Marci A. Landsmann
-
Medicare Coverage for Next-Generation Sequencing TestsMultigene panels that rely on next-generation sequencing are increasingly used to test for hereditary cancer risk-related mutations. The federal government aims to expand Medicare coverage for these tests.
by Ashley P. Taylor
-
On Cancer and IdentityThe first time Liza Bernstein was diagnosed with cancer, she wouldn't allow it to be part of her identity. After her third cancer diagnosis, she became an advocate for other patients.
by Liza Bernstein
-
Telling Your Children About Inheritable Cancer RiskLetting children know they might have a mutation that increases their risk for cancer can be a challenge for patients. Experts stress there is no right or wrong way to share the information.
by Marci A. Landsmann
-
Forward Look
Early Chemotherapy Dose Reductions May Affect Breast Cancer OutcomesNew study explores impact of lowering dose due to side effects.
by Jane Langille
-
Turning Up the Heat on CancerResearchers are working to expand the benefits of immunotherapy by making “cold” tumors “hot” so they can respond better to treatments.
by Kendall K. Morgan
-
Secure ConnectionsPatients find each other online and get support they say is unparalleled, but with openness comes concern about privacy.
by Kate Yandell
-
BRCA: Who Should Be Tested?Genetic testing for mutations in the BRCA1 and BRCA2 genes creates opportunities for cancer risk reduction. But 25 years after the mutations were discovered, some who could benefit from testing are still left out.
by Sue Rochman
-
Cancer Patient Advocates Find Strength in NumbersPatient advocates have become a vital part of the San Antonio Breast Cancer Symposium. Opportunities for advocates continue to multiply.
by Marci A. Landsmann
-
Exploring Immunotherapy for Triple Negative Breast CancerFollowing the approval of the first immunotherapy for breast cancer by the U.S. Food and Drug Administration in March 2019, experts at the San Antonio Breast Cancer Symposium discussed avenues for further development.
by Marci A. Landsmann
